Product description

Rilexine is a antimicrobial chewable tablet for dogs.

Active ingredients

Each Rilexine tablet contains:

Indications for use

Rilexine is indicated for the treatment of secondary superficial bacterial pyoderma in dogs caused by susceptible strains of Staphylococcus pseudintermedius.

Administration and dosage

• The recommended dose is 22 mg/kg (10 mg/lb) of body weight twice daily for 28 days.

• Appropriate culture and susceptibility tests should be performed before treatment to determine the causative organism and its susceptibility to cephalexin. Therapy with Rilexine Chewable Tablets may be initiated before results of these tests are known; once the results become available, antimicrobial therapy should be adjusted accordingly. If acceptable response to treatment is not observed, then the diagnosis should be re-evaluated and appropriate alternative therapy considered.

Prescribing information